08:38 AM EST - Bausch + Lomb Corporation : Announced positive 24-month results from the pivotal U.S. clinical trial of the ELIOS System. Developed for the treatment of elevated intraocular pressure (IOP) in patients with open angle glaucoma, ELIOS is an implant-free procedure that uses next generation excimer laser technology. Bausch + Lomb Corporation
shares T.BLCO are trading unchanged at $22.14.
